Bioscience News - GEG Tech top picks

Moffitt Cancer Center, a national leader in cancer care and research and the only National Cancer Institute-designated cancer center in Florida, is presenting new data from dozens of clinical research studies at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, the largest clinical cancer research meeting in the world. Moffitt investigators will lead 25 abstract presentations, five educational sessions, two cancer panels and two clinical science symposia. The virtual meeting will take place June 4-8, 2021. Among those presenting will be Dr. Bijal Shah, who will discuss the results of the Phase 2 ZUMA-3 trial evaluating CAR T-cell therapy for adults with acute lymphoblastic leukemia, a difficult-to-treat malignancy in this patient population. Also on hand will be Dr. Frederick Locke, who will present data from the ALPHA2 trial evaluating ALLO-501, an allogeneic CAR T-cell therapy product, in combination with ALLO-647, a monoclonal antibody that depletes lymphocytes in the body to help prepare the patient to receive new immune cells, in patients with large B-cell lymphoma.

Biology is the unparalleled master of additive manufacturing. Observing the formation of biomaterials, like wood or bone, allows biologists and material scientists to see what would be physically possible if we employed complex, multi-component feedstocks and non-equilibrium processes in our own additive manufacturing. Furthermore, while biomimicry of such hierarchical materials would undoubtedly increase the complexity and sophistication of our products, that is only part of the benefit.

A majority of children would be conceived in laboratories instead of naturally in developed countries in two decades from now, says a leading academic at the Stanford University. Henry Greely, Director at the Center for Law and the Biosciences, Stanford University, believes that the process of conception could even become stigmatised in the future, the Independent reported.